Popliteal Artery Entrapment Syndrome & TRanscutaneoUS Oxymetry

Popliteal Entrapment Syndrome Clinical Trial

— PETRUS  

Official title:

Application de l'oxymétrie Dynamique Pour le Diagnostic Des pièges artériels poplités

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03356379
• Other study ID #: 2017-AO1887-46
• Status: Completed
• Phase: N/A
• Start date: November 22, 2017
• Est. completion date: November 15, 2019

Study information

• Verified date: November 2019
• Source: University Hospital, Angers
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim of the study is to test the feasibility of transcutaneous oxygen pressure (TcPO2) recording in the diagnosis of popliteal entrapment syndrome (PES) in 30 patients with suspected PES and 30 asymptomatic control heathy subjects

Description:

Patients suspected of PES and healthy cpontrols after detailled explanation of the protocol will have a recording of tcpO2 on both calves and will perform a series of elevation on foot in the standing position.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: November 15, 2019
• Est. primary completion date: November 15, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age over 18 years

• Insurance company alffiliation Symptoms consistent with PES (patients) or absence of symptoms (controls)

Exclusion Criteria:

• Refuse to participate Exclusion period from another protocole

Related Conditions & MeSH terms

• Popliteal Entrapment Syndrome
• Syndrome

Intervention

Diagnostic Test:
• Transcutaneous oximetry
Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves

Locations

Country	Name	City	State
France	CHU Angers	Angers

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of a significant DROP decrease	Comparison of DROP value between PES patients and controls	1 hour